WATCH: Viltepso, An FDA-Approved Treatment for Patients Amenable to Exon 53 Skipping – Webinar Recording
PPMD and NS Pharma hosted a community webinar on March 2, 2023 to discuss VILTEPSO, an FDA-approved treatment for patients with Duchenne amenable to exon 53 skipping. Mathula Thangarajh, MD joined us to discuss the…Learn More